153,029 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Bought by Two Sigma Investments LP

Two Sigma Investments LP acquired a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 153,029 shares of the medical instruments supplier's stock, valued at approximately $552,000. Two Sigma Investments LP owned about 0.21% of OraSure Technologies as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in OSUR. Systematic Financial Management LP lifted its stake in OraSure Technologies by 33.7% in the fourth quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier's stock worth $6,042,000 after purchasing an additional 421,497 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of OraSure Technologies by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,327 shares of the medical instruments supplier's stock worth $73,000 after purchasing an additional 6,689 shares during the last quarter. Man Group plc boosted its stake in shares of OraSure Technologies by 70.0% during the fourth quarter. Man Group plc now owns 236,703 shares of the medical instruments supplier's stock valued at $854,000 after purchasing an additional 97,448 shares during the period. Millennium Management LLC lifted its holdings in OraSure Technologies by 16.7% during the 4th quarter. Millennium Management LLC now owns 2,158,450 shares of the medical instruments supplier's stock valued at $7,792,000 after buying an additional 308,420 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in OraSure Technologies by 76.5% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 926,608 shares of the medical instruments supplier's stock worth $3,345,000 after acquiring an additional 401,658 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on OSUR shares. Wall Street Zen raised OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, May 17th. Evercore ISI restated an "in-line" rating and set a $3.00 price target on shares of OraSure Technologies in a research note on Monday, May 19th.

OraSure Technologies Stock Up 0.3%

OSUR stock traded up $0.01 during trading on Thursday, hitting $2.93. 771,220 shares of the company's stock traded hands, compared to its average volume of 841,964. OraSure Technologies, Inc. has a 1 year low of $2.36 and a 1 year high of $4.92. The firm has a market capitalization of $219.16 million, a P/E ratio of 19.53 and a beta of 0.43. The business has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $3.41.

OraSure Technologies announced that its Board of Directors has initiated a share buyback program on Monday, March 24th that permits the company to buyback $40.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 15.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.